<DOC>
	<DOCNO>NCT02113319</DOCNO>
	<brief_summary>In patient Core Binding Factors Acute Myelogenous Leukemia , level Minimal Residual Disease chemotherapy predictive relapse . The relapse risk also increase case mutation receptor tyrosine kinase . For patient high Minimal Residual Disease level end consolidation molecular relapse , maintenance inhibitor dasatinib propose .</brief_summary>
	<brief_title>Study Assess Dasatinib Patients With Core Binding Factors Acute Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Patient present de novo secondary Core Binding Factors Acute Myelogenous Leukemia Patient first present one follow criterion : `` Resistant '' Patient : decrease le 3 log Acute Myelogenous Leukemia transcript level bone marrow 2 consolidation Patient `` molecular relapse `` : increase 1 log Core Acute Myelogenous Leukemia transcript level two successive marrow sample Woman childbearing potential Concurrent incurable malignacy Acute Myelogenous Leukemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Core Binding Factors</keyword>
	<keyword>Acute Myelogenous Leukemia refractory conventional chemotherapy</keyword>
	<keyword>molecular relapse</keyword>
</DOC>